Spatial Proteomic Analysis of Isogenic Metastatic Colorectal Cancer Cells Reveals Key Dysregulated Proteins Associated with Lymph Node, Liver, and Lung Metastasis.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
27 01 2022
Historique:
received: 31 12 2021
revised: 22 01 2022
accepted: 25 01 2022
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 9 4 2022
Statut: epublish

Résumé

Metastasis is the primary cause of colorectal cancer (CRC) death. The liver and lung, besides adjacent lymph nodes, are the most common sites of metastasis. Here, we aimed to study the lymph nodes, liver, and lung CRC metastasis by quantitative spatial proteomics analysis using CRC cell-based models that recapitulate these metastases. The isogenic KM12 cell system composed of the non-metastatic KM12C cells, liver metastatic KM12SM cells, and liver and lung metastatic KM12L4a cells, and the isogenic non-metastatic SW480 and lymph nodes metastatic SW620 cells, were used. Cells were fractionated to study by proteomics five subcellular fractions corresponding to cytoplasm, membrane, nucleus, chromatin-bound proteins, and cytoskeletal proteins, and the secretome. Trypsin digested extracts were labeled with TMT 11-plex and fractionated prior to proteomics analysis on a Q Exactive. We provide data on protein abundance and localization of 4710 proteins in their different subcellular fractions, depicting dysregulation of proteins in abundance and/or localization in the most common sites of CRC metastasis. After bioinformatics, alterations in abundance and localization for selected proteins from diverse subcellular localizations were validated via WB, IF, IHC, and ELISA using CRC cells, patient tissues, and plasma samples. Results supported the relevance of the proteomics results in an actual CRC scenario. It was particularly relevant that the measurement of GLG1 in plasma showed diagnostic ability of advanced stages of the disease, and that the mislocalization of MUC5AC and BAIAP2 in the nucleus and membrane, respectively, was significantly associated with poor prognosis of CRC patients. Our results demonstrate that the analysis of cell extracts dilutes protein alterations in abundance in specific localizations that might only be observed studying specific subcellular fractions, as here observed for BAIAP2, GLG1, PHYHIPL, TNFRSF10A, or CDKN2AIP, which are interesting proteins that should be further analyzed in CRC metastasis.

Identifiants

pubmed: 35159257
pii: cells11030447
doi: 10.3390/cells11030447
pmc: PMC8834500
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI20CIII/00019
Organisme : Research Foundation-Flanders
ID : ZW15_09-G0H6316N
Organisme : Flemish government through long-term structural funding Methusalem
ID : CASAS2, Meth/15/04
Organisme : financial support of the KU Leuven
ID : KU Leuven (C14/16/053)
Organisme : The Flanders Research Foundation (FWO) predoctoral contract
ID : grant number 1193818N
Organisme : Spanish Ministerio de Educación, Cultura y Deporte
ID : Predoctoral contrac to Ana Montero-Calle

Références

Clin Exp Metastasis. 2004;21(7):571-9
pubmed: 15787094
Oncotarget. 2018 Jan 24;9(13):10847-10867
pubmed: 29541381
Biochim Biophys Acta. 2014 Aug;1846(1):13-25
pubmed: 24709009
J Proteomics. 2012 Aug 3;75(15):4647-55
pubmed: 22465712
Clin Exp Metastasis. 2015 Jun;32(5):457-65
pubmed: 25899064
Traffic. 2015 Oct;16(10):1039-61
pubmed: 26172624
Cancer Res. 2001 Nov 1;61(21):7792-7
pubmed: 11691794
Eur J Cancer. 2015 Oct;51(15):2158-2168
pubmed: 26421819
J Proteome Res. 2010 Jan;9(1):545-55
pubmed: 19924834
Anal Chem. 2015 Apr 21;87(8):4110-6
pubmed: 25837572
Clin Cancer Res. 2003 Oct 15;9(13):4802-10
pubmed: 14581351
Cancer Res. 1988 Apr 1;48(7):1943-8
pubmed: 3349467
J Cell Physiol. 2019 Aug;234(10):17280-17294
pubmed: 30784076
Nat Rev Mol Cell Biol. 2019 May;20(5):285-302
pubmed: 30659282
Med Sci Monit. 2019 Apr 09;25:2583-2590
pubmed: 30962415
NPJ Precis Oncol. 2019 Aug 21;3:20
pubmed: 31453371
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Mol Cell Proteomics. 2009 Oct;8(10):2382-95
pubmed: 19638618
Sci Rep. 2019 Sep 19;9(1):13547
pubmed: 31537884
Sci Rep. 2016 Jul 15;6:29765
pubmed: 27416752
Proteomics Clin Appl. 2009 Jul;3(7):841-52
pubmed: 21136991
Cancers (Basel). 2015 Jul 31;7(3):1436-46
pubmed: 26264025
Cancer Manag Res. 2019 Feb 13;11:1337-1348
pubmed: 30863148
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
PLoS One. 2013 May 16;8(5):e63695
pubmed: 23696849
Mol Cancer. 2020 Feb 25;19(1):37
pubmed: 32098629
Clin Cancer Res. 2008 Nov 1;14(21):7050-9
pubmed: 18981002
Virchows Arch. 2016 Sep;469(3):255-65
pubmed: 27298226
Cancer Res. 2001 Jul 1;61(13):4942-6
pubmed: 11431320
J Proteomics. 2020 Mar 1;214:103635
pubmed: 31918032
Cancers (Basel). 2021 Feb 14;13(4):
pubmed: 33672863
Mol Cell Proteomics. 2011 Oct;10(10):M110.005397
pubmed: 21622897
Oncogene. 2016 Aug 4;35(31):4112-21
pubmed: 26751774
World J Gastroenterol. 2015 Sep 28;21(36):10453-60
pubmed: 26420972
Cancer Cell. 2012 Nov 13;22(5):571-84
pubmed: 23153532
Cancer Res. 2012 Jun 1;72(11):2780-90
pubmed: 22505647
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cancer Res. 1988 Dec 1;48(23):6863-71
pubmed: 2846163
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Nat Rev Methods Primers. 2021;1:
pubmed: 34549195
Nat Cell Biol. 2019 May;21(5):627-639
pubmed: 30988423
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Oncogenesis. 2018 May 11;7(5):39
pubmed: 29748568
Mol Cell Proteomics. 2017 May;16(5):873-890
pubmed: 28325852
J Proteome Res. 2011 Oct 7;10(10):4373-87
pubmed: 21854069
Genomics Proteomics Bioinformatics. 2004 Aug;2(3):152-66
pubmed: 15862116
Crit Rev Oncol Hematol. 2017 Jan;109:9-19
pubmed: 28010901
Clin Cancer Res. 2013 Nov 1;19(21):6006-19
pubmed: 24025712
Front Cell Dev Biol. 2021 Apr 15;9:656359
pubmed: 33937255
Small GTPases. 2018 Mar 4;9(1-2):158-181
pubmed: 29239692
Cancer Res. 2019 Feb 1;79(3):546-556
pubmed: 30538120
Genes Dev. 2017 Jul 15;31(14):1439-1455
pubmed: 28827399
Cytogenet Cell Genet. 1999;84(1-2):75-82
pubmed: 10343108
Proteomics. 2017 Oct;17(19):
pubmed: 28861940
Sci Rep. 2013 Oct 15;3:2938
pubmed: 24126910

Auteurs

Guillermo Solís-Fernández (G)

Molecular Imaging and Photonics Division, Chemistry Department, Faculty of Sciences, KU Leuven, Celestijnenlaan 200F, 3001 Leuven, Belgium.
Chronic Disease Programme, UFIEC, Instituto de Salud Carlos III, 28220 Madrid, Spain.

Ana Montero-Calle (A)

Chronic Disease Programme, UFIEC, Instituto de Salud Carlos III, 28220 Madrid, Spain.

Javier Martínez-Useros (J)

Translational Oncology Division, OncoHealth Institute, Health Research Institute-Fundacion Jimenez Diaz University Hospital, 28040 Madrid, Spain.

Álvaro López-Janeiro (Á)

Molecular Pathology and Therapeutic Targets Group, La Paz University Hospital (IdiPAZ), 28046 Madrid, Spain.

Vivian de Los Ríos (V)

Proteomics Facility, Centro de Investigaciones Biológicas (CIB-CSIC), 28039 Madrid, Spain.

Rodrigo Sanz (R)

Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.

Jana Dziakova (J)

Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.

Elena Milagrosa (E)

Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.

María Jesús Fernández-Aceñero (MJ)

Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.

Alberto Peláez-García (A)

Molecular Pathology and Therapeutic Targets Group, La Paz University Hospital (IdiPAZ), 28046 Madrid, Spain.

José Ignacio Casal (JI)

Centro de Investigaciones Biológicas (CIB-CSIC), Department of Molecular Biomedicine, 28039 Madrid, Spain.

Johan Hofkens (J)

Molecular Imaging and Photonics Division, Chemistry Department, Faculty of Sciences, KU Leuven, Celestijnenlaan 200F, 3001 Leuven, Belgium.

Susana Rocha (S)

Molecular Imaging and Photonics Division, Chemistry Department, Faculty of Sciences, KU Leuven, Celestijnenlaan 200F, 3001 Leuven, Belgium.

Rodrigo Barderas (R)

Chronic Disease Programme, UFIEC, Instituto de Salud Carlos III, 28220 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH